Oncotech

The bank, formerly owned by Oncotech, contains more than 144,000 discrete cancer samples.

No mention was made of a number of other miRNA diagnostics projects, suggesting that the Danish company has put these on hold as part of a scale-back of its efforts in the area.

Despite the setback, Exiqon remains on track with its strategy of marketing its microRNA-based diagnostics in collaboration with partners, and expects to announce a deal before the end of the year, a company official said.

The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.